Recently, new treatment strategies, such as FLT3 inhibitors, IDH inhibitors, nuclear exporter inhibitors, and immune therapies, are introduced to regulate genetic expression and immunological responses in AML (48). The gene discussed is FLT3; the disease is acute myeloid leukemia.